Medical devices, healthcare technology and the business of care
PMA approval · P100020

COBAS HPV TEST

Roche Molecular Systems, Inc. · Decision date Apr 19, 2011

MEDTECHLEDGER EXPLANATIONP100020

What did the FDA approve?

FDA approved the cobas HPV Test from Roche Molecular Systems, Inc. on April 19, 2011. The device is a qualitative in vitro PCR and nucleic acid hybridization test that detects 14 high-risk HPV types in one analysis, specifically identifying HPV 16 and HPV 18 while concurrently detecting types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

The approved indications cover patients 21 years and older with ASC-US cervical cytology results to determine need for colposcopy referral and to assess presence or absence of HPV genotypes 16 and 18. In women 30 years and older, the test can be used adjunctively with cervical cytology to screen for high-risk HPV types, and to assess presence or absence of genotypes 16 and 18. The approval order contains additional statement detail not reproduced in the database entry.

FDA approval order statement

APPROVAL FOR THE COBAS HPV TEST. COBAS HPV TEST INDICATIONS FOR USE: THE COBAS HPV TEST IS A QUALITATIVE IN VITRO TEST FOR THE DETECTION OF HUMAN PAPILLOMAVIRUS (HPV) IN PATIENT SPECIMENS. THE TEST UTILIZES AMPLIFICATION OF TARGET DNA BY THE POLYMERASE CHAIN REACTION (PCR) AND NUCLEIC ACID HYBRIDIZATION FOR THE DETECTION OF 14 HIGH-RISK (HR) HPV TYPES IN A SINGLE ANALYSIS. THE TEST SPECIFICALLY IDENTIFIES TYPES HPV 16 AND HPV 18 WHILE CONCURRENTLY DETECTING THE REST OF THE REST OF THE HIGH RISK TYPES (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 AND 68). THE COBAS HPV TEST IS INDICATED: 1) TO SCREEN PATIENTS 21 YEARS AND OLDER WITH ASC-US (ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE) CERVICAL CYTOLOGY TEST RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY; AND 2) TO BE USED IN PATIENTS 21 YEARS AND OLDER WITH ASC-US CERVICAL CYTOLOGY RESULTS, TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV GENOTYPES 16 AND 18. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TO COLPOSCOPY; 3) IN WOMEN 30 YEARS AND OLDER, THE COBAS HPV TEST CAN BE USED WITH CERVICAL CYTOLOGY TO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH RISK HPV TYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT; AND 4) IN WOMEN 30 YEARS AND OLDER, THE COBAS HPV TEST CAN BE USED TO ASSESS THE PRESENCE OR ABSENCE OF HPV GENOTYPES 16 AND 18. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN¿S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT....(SEE APPROVAL ORDER FOR ADDITIONAL APPROVAL STATEMENT DETAIL).
Regulatory pathway
Original PMA
Clinical specialty
Microbiology
Decision date
Apr 19, 2011

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P100020
Regulatory pathway
Premarket approval application
Product code
MAQ
Decision code
APPR
Decision date
Apr 19, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P100020 received

    Application receipt date recorded by FDA.

  2. P100020 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P100020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100020

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Abbott Molecular, Inc.PMA approvalNov 1, 2023FDA
Roche Molecular Systems, Inc.PMA approvalApr 3, 2020FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records